SD

Sanjay Desai

Director Director DIN 01872945
DIN 01872945 First appointment Mar 2008 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2008
Shareholding value β€’β€’β€’β€’ Premium profile

About Sanjay Desai

Data last updated:

Sanjay Desai was a Director at Alivus Life Sciences Limited (2011–2018) and Director at Acia Lab Private Limited (from 2008). The companies operate in Pharma.

DIN 01872945
Primary Designation Director
Industry Pharma
First Appointment 12 Mar 2008
Oldest Company Age 18 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Alivus Life Sciences Limited L74900PN2011PLC139963
Director23 Jun 20112011₹2,421 Cr (FY 2025)Active
Acia Lab Private Limited U24110PN2008PTC131592
Director12 Mar 20082008Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Acia Lab Private Limited
Alivus Life Sciences Limited
Premium access

Shareholding and investment profile for Sanjay Desai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sanjay Desai

Sanjay Desai was first appointed on 12 Mar 2008 as Director at Acia Lab Private Limited. The most recent appointment on record is 23 Jun 2011 at Alivus Life Sciences Limited.

Sanjay Desai held 2 earlier board appointments: Alivus Life Sciences Limited (Director, 23 Jun 2011 to 16 Jul 2018); Acia Lab Private Limited (Director, from 12 Mar 2008).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available